



Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

MANAGEMENT BOARD

I, Marco Greco

Organisation/Company: Forum Des Patients Europeens

Country: Belgium

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical companies and in medical device companies are those listed below:

Pharmaceutical company interests

1.1 Employment

No interest declared

1.2 Consultancy

No interest declared

1.3 Strategic advisory role

No interest declared

1.4 Financial interests

No interest declared

1.5 Principal investigator

No interest declared

1.6 Investigator

No interest declared

1.7 Grant / Funding to organisation/institution

Name of pharmaceutical company	Subject Matter
NV Janssen Ph.	eur 70,000 support to EPF workplan 2023 and EPF 20th An. Event
Takeda Ph. Int.	eur 90,000 support to EPF Capacity Building Programme 2023, 2023 HTA Capacity Building Simulation Workshop, Data Saves Lives and EPF 20th An. Event
Galapagos NV	eur 20,000 support to EPF 20th An. Event
Amgen	eur 25,000 support to EPF workplan 2023
IQVIA	eur 10,000 support to EPF 20th An. Event
Medicines for	eur 20,000 support to EPF workplan 2023

Europe	
Novo Nordisk Denmark	eur 26,000 support to EPF Capacity Building Programme
EPFIA	eur 85,000 support to Data Saves Lives, EPF workplan 2023 and EPF 20th An. Event
Astellas Pharma Europe	Eur 10,000 support to 2023 HTA Capacity Building simulation Workshop
Baxter World Trade	eur 20,000 support to EPF workplan 2023 and EPF 20th An. Event
MSD Belgium	eur 30,000 support to EPF HTA Capacity Building Simulation Workshop
Pfizer INC	eur 70,000 support to EPF workplan 2023, EPF HTA Capacity Building Simulation Workshop, and EPF 20th An. Event
Boehringer Ingelheim	eur 45,000 support to EPF workplan 2023 and EPF 20th An. Event
UCB Biopharma SPRL	eur 25,000 support to EPF workplan 2023 and EPF 20th An. Event
Daiichi Sankyo Europe GmbH	eur 30,000 support to EPF Capacity Building Programme 2023
Servier Affaires Medicales	eur 20,000 support to EPF 20th An. Event
Novocure	eur 40,411,01 support to EPF Capacity Building Programme
Merk	Eur 40,000 EPF 20th An. Event
Chiesi Farmaceutici Spa	eur 25,000 support to EPF workplan 2023
Abbvie	eur 35,000 support to EPF workplan 2023
H. Lundbeck A/S	eur 10,000 support to EPF 20th An. Event
Bristol Myers Squibb	eur 60,000 support to EPF workplan 2023
Vertex Pharmaceuticals Europe	eur 14,000 support to EPF 20th An. Event
GlaxoSmithKline	eur 60,000 support to EPF workplan 2023 and EPF Capacity Building Programme
Viartis	eur 20,000 support to EPF 20th An. Event
Sanofi-Aventis Group	eur 50,000 support to EPF workplan
Edwards Lifesciences	eur 25,000 support to EPF workplan 2023
Horizon Therapeutics	eur 90,000 support to EPF workplan 2023, EPF Capacity Building Programme, and EPF 20th An. Event
F. Hoffmann-La Roche Ltd.	eur 110,000 support to EPF workplan 2023, Data Saves lives, and EPF 20th An. Event
Merck Sharp & Dohme Corp.	eur 73,698,81 support to EPF Capacity Building Programme and EPF 20th An. Event
Novavax GmbH	eur 35,000 support to EPF Capacity Building Programme 2023 and EPF 20th An. Event
Novartis Pharma AG	eur 115,000 support to EPF workplan 2023, 2023 HTA Capacity Building Simulation Workshop, Data Saves Lives and EPF 20th An. Event
Grunenthal GmbH	eur 5,000 support to EPF 20th An. Event

1.8 Close family member interest

No interest declared

1.9 Personal interests, other than interests in a pharmaceutical company

No interest declared

1.10 Any other interests or facts

I'm a volunteer and actually President of the board of the European Patients' Forum. EPF receives its funding from a diversified range of sources: membership fees; project funding from the European Commission; unrestricted grants from commercial companies.

details of EPF's funders, funding arrangements and accounts are available on its website:
http://www.eu_patient.eu/About_EPf/Transparency/

Medical device company interests

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No interest declared

2.7 Grant / Funding to organisation/institution

Name of medical device company	Subject Matter
Medtech Europe	Eur 10,000 Data Saves Lives
Intuitive Surgical Sarl	eur 20,000 support to EPF workplan 2023 and EPF 20th An. Event

2.8 Close family member interest

No interest declared

2.9 Personal interests, other than interests in a medical device company

No interest declared

2.10 Any other interests or facts

I'm a volunteer and actually President of the board of the European Patients' Forum. EPF receives its funding from a diversified range of sources: membership fees; project funding from the European Commission; unrestricted grants from commercial companies.

details of EPF's funders, funding arrangements and accounts are available on its website:
http://www.eu_patient.eu/About_EPF/Transparency/

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party ¹ any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.

Full Name:	Marco Greco
------------	-------------

Date:	2024-09-04
-------	------------

For Definitions of activities etc, refer to the policy on handling of competing interests.